SCHEMBL24958741

SCHEMBL24958741

OCc1cc(C(F)(F)F)ns1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.33
SMARCA4 P51532 1/20 0.33
LOX P28300 1/20 0.32
LOXL2 Q9Y4K0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9135341 0.69 PLOD2 (0.43) SMARCA2SMARCA4
SCHEMBL8119362 0.69
SCHEMBL9135866 0.68 MAPT (0.42) SMARCA2SMARCA4
SCHEMBL17198902 0.67 HSP90AA1 (0.38) SMARCA2SMARCA4
SCHEMBL21722751 0.67 CA2 (0.40) SMARCA2SMARCA4LOXLOXL2
SCHEMBL24525054 0.67 SMARCA2 (0.35) SMARCA2SMARCA4
SCHEMBL24958740 0.65 DAO (0.41) SMARCA2SMARCA4
SCHEMBL31532336 0.65 TSHR (0.38)
SCHEMBL25183576 0.64 CDK8 (0.37) SMARCA2SMARCA4
SCHEMBL410519 0.62 NOTUM (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4691554-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
EP-4520393-A2 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-03-12 EP disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 US disclosed
CN-117295729-A Carboxy-benzimidazole GLP-1R modulating compounds 吉利德科学公司 2023-12-26 CN disclosed
CN-117279905-A Carboxy-benzimidazole GLP-1R modulating compounds 吉利德科学公司 2023-12-22 CN disclosed
EP-4271674-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-08 EP disclosed
EP-4271672-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-08 EP disclosed
US-20230021705-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-01-26 US disclosed
WO-2022225941-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-27 WO disclosed
WO-2022225914-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230021705-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 SMARCA2 4231/4885SMARCA4 4004/4885LOX 2842/4885
US-11858918-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 SMARCA2 4231/4885SMARCA4 4004/4885LOX 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.